Scott Lassman: The Challenge of Drug Importation
January 31st 2018Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, explains some of the challenges with proposals to allow the United States to import cheaper drugs from Canada or other highly regulated pharmaceutical markets.
Molly Burich: Biosimilar Regulation and Policy in the European Union and the United States
November 23rd 2017Molly Burich, MS, associate director of public policy: biosimilars, pipeline, and reimbursement at Boehringer Ingelheim, discusses major regulatory and policy differences between the European Union and the United States.